| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Molecular Pharmacology [Y. P., D. K., J. M. C.] and Cytogenetic Clinical Oncology Section, Medicine Branch [C-S. K-S., J. W-P.], Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland 20892
4'-(9-Acridinylamino)methanesulfon-m-anisidide, etoposide, and 2-methyl-9-hydroxyellipticinium are antitumor topoisomerase II (topo II) inhibitors. The relationship between drug-induced sister chromatid exchanges (SCEs) or chromosomal aberrations and cytotoxicity was investigated in Chinese hamster cells sensitive (DC3F) and resistant (DC3F/9-OHE) to topo II inhibitors. Thirty-min drug treatments produced SCEs and chromosomal aberrations in sensitive (DC3F) cells, 4'-(9-acridinylamino)methanesulfon-m-anisidide being more potent than etoposide or 2-methyl-9-hydroxyellipticinium at equimolar concentrations. Comparable treatments of resistant (DC3F/9-OHE) cells did not produce chromosomal damage. The cytotoxicity of 4'-(9-Acridinylamino)-methanesulfon-m-anisidide was also greater than that of etoposide or 2-methyl-9-hydroxyellipticinium in DC3F cells, and no cytotoxicity was observed in DC3F/9-OHE at drug concentrations that produced more than two logs of cell kill in DC3F cells. A plot of cytotoxicity versus SCEs showed a good correlation between the two parameters. Therefore, short treatments of mammalian cells with topo II inhibitors produce reversible topo II-mediated DNA breaks which are associated with chromosomal aberrations and SCEs whose number correlates with cytotoxicity. In addition, topo II mutant DC3F/9-OHE cells were more sensitive than DC3F cells to the chromosomal, DNA cross-linking and cytotoxic effects of mitomycin C and were equally sensitive to the cytotoxic effect of camptothecin.
1 To whom requests for reprints should be addressed, at Building 37, Room 5A19, National Cancer Institute, Division of Cancer Treatment, NIH, 9000 Rockville Pike, Bethesda, MD 20892.
Received 3/11/86. Revised 9/28/87. Accepted 10/26/87.
This article has been cited by other articles:
|
|
 |
|
  A. Zhang, Y. L. Lyu, C.-P. Lin, N. Zhou, A. M. Azarova, L. M. Wood, and L. F. Liu A Protease Pathway for the Repair of Topoisomerase II-DNA Covalent Complexes J. Biol. Chem., November 24, 2006; 281(47): 35997 - 36003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Adachi, H. Suzuki, S. Iiizumi, and H. Koyama Hypersensitivity of Nonhomologous DNA End-joining Mutants to VP-16 and ICRF-193: IMPLICATIONS FOR THE REPAIR OF TOPOISOMERASE II-MEDIATED DNA DAMAGE J. Biol. Chem., September 19, 2003; 278(38): 35897 - 35902. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Hong and K. N. Kreuzer Endonuclease cleavage of blocked replication forks: An indirect pathway of DNA damage from antitumor drug-topoisomerase complexes PNAS, April 29, 2003; 100(9): 5046 - 5051. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. A. Stohr and K. N. Kreuzer Repair of Topoisomerase-Mediated DNA Damage in Bacteriophage T4 Genetics, May 1, 2001; 158(1): 19 - 28. [Abstract] [Full Text]
|
|
|
|
|
|
S.-W. Ng, J. P. Eder, L. E. Schnipper, and V. T. W. Chan Molecular Cloning and Characterization of the Promoter for the Chinese Hamster DNA Topoisomerase IIalpha Gene J. Biol. Chem., October 27, 1995; 270(43): 25850 - 25858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Mao, S. D. Desai, C.-Y. Ting, J. Hwang, and L. F. Liu 26 S Proteasome-mediated Degradation of Topoisomerase II Cleavable Complexes J. Biol. Chem., October 26, 2001; 276(44): 40652 - 40658. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |
